Capricor Therapeutics Inc’s recently made public that its 10% Owner Nippon Shinyaku Co Ltd acquired Company’s shares for reported $15.0 million on Sep 20 ’24. In the deal valued at $5.36 per share,2,798,507 shares were bought. As a result of this transaction, Nippon Shinyaku Co Ltd now holds 7,090,351 shares worth roughly $44.95 million.
Piper Sandler initiated its Capricor Therapeutics Inc [CAPR] rating to an Overweight in a research note published on October 21, 2024; the price target was $35. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in mid May with a ‘”an Outperform”‘ rating. Cantor Fitzgerald began covering CAPR with “an Overweight” recommendation on January 05, 2024. Ladenburg Thalmann started covering the stock on October 26, 2022. It rated CAPR as “a Buy”.
Price Performance Review of CAPR
On Friday, Capricor Therapeutics Inc [NASDAQ:CAPR] saw its stock fall -9.04% to $6.34. Over the last five days, the stock has lost -46.54%. Capricor Therapeutics Inc shares have fallen nearly -54.06% since the year began. Nevertheless, the stocks have risen 16.12% over the past one year. While a 52-week high of $23.40 was reached on 02/18/25, a 52-week low of $3.52 was recorded on 05/09/25. SMA at 50 days reached $11.43, while 200 days put it at $12.42.
Levels Of Support And Resistance For CAPR Stock
The 24-hour chart illustrates a support level at 6.04, which if violated will result in even more drops to 5.74. On the upside, there is a resistance level at 6.87. A further resistance level may holdings at 7.40. The Relative Strength Index (RSI) on the 14-day chart is 27.28, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.26, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 99.14%. Stochastics %K at 2.41% indicates the stock is a buying.
